Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients [0.03%]
恩拉普利预防乳腺癌和淋巴瘤患者高剂量蒽环类药物治疗后的心脏毒性
Daniela Cardinale,Giancarlo Marenzi
Daniela Cardinale
Reply: Balancing Promise and Evidence: Critical Perspectives on SGLT2 Inhibitors for Cardiotoxicity Prevention [0.03%]
关于SGLT2抑制剂预防心血管毒性的回复：批判性视角——平衡承诺与证据
Ammar W Bhatti,Bhargav Makwana,Sumanth Khadke et al.
Ammar W Bhatti et al.
Balancing Promise and Evidence: Critical Perspectives on SGLT2 Inhibitors for Cardiotoxicity Prevention [0.03%]
权衡希望与证据：钠-葡萄糖协同转运蛋白2抑制剂防治心血管毒性的批判性观点
Paschalis Karakasis,Dimitrios Patoulias,Nikolaos Fragakis
Paschalis Karakasis
Reply: Reassessing CAC Risk Post-RRSO: The Overlooked Role of Hormone Therapy [0.03%]
BRCA相关卵巢癌术后激素治疗的忽视作用及其对复发风险的影响评估回复信
Maarten J Beekman,Lara Terra,Bernadette A M Heemskerk-Gerritsen et al.
Maarten J Beekman et al.
Reassessing CAC Risk Post-RRSO: The Overlooked Role of Hormone Therapy [0.03%]
绝经后接受过双侧输卵管卵巢切除术妇女的CAC风险再评估：被忽视的激素治疗作用
Binglin Li,Yan Wang,Ruijuan Chen
Binglin Li
Long-Term Care of Childhood Cancer Survivors at Risk for Cardiac Late Effects [0.03%]
儿童癌症幸存者长期心脏后遗症的护理风险评估
Aaron Ackerman,Daniel Ly,Monica Hall et al.
Aaron Ackerman et al.
Severe Aortic Stenosis and Chronic Myeloid Leukemia: Considerations for Valve Management [0.03%]
重度主动脉瓣狭窄合并慢性粒细胞白血病患者人工机械瓣膜抗凝治疗的利弊分析及管理建议
Rebecca Cunningham,Sang Gune K Yoo,Alexander A Brescia et al.
Rebecca Cunningham et al.
Rechallenge After Severe Immune Checkpoint Inhibitor Myocarditis: Venturing Into the Unknown [0.03%]
严重免疫检查点抑制剂心肌炎后再挑战：探索未知领域
Guillaume Bailly,Maxime Robert-Halabi,Pierre-Adrien Vion et al.
Guillaume Bailly et al.
Intermuscular Fat and Physical Activity Levels Relative to Exercise Capacity Change During Breast Cancer Treatment [0.03%]
乳腺癌治疗期间跨肌肉脂肪和身体活动水平相对于运动能力的变化
Lauren Daniel,Moriah P Bellissimo,Ralph B D&#x;Agostino Jr et al.
Lauren Daniel et al.
Nowell M Fine
Nowell M Fine